Chiral phase analysis of warfarin enantiomers in patient plasma in relation to CYP2C9 genotype
- 15 June 1998
- journal article
- Published by Elsevier in Journal of Chromatography B: Biomedical Sciences and Applications
- Vol. 710 (1-2), 143-148
- https://doi.org/10.1016/s0378-4347(98)00099-1
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Genetic association between sensitivity to warfarin and expression of CYP2C9*3Pharmacogenetics, 1997
- The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductasePharmacogenetics, 1997
- Genetic analysis of the human cytochrome P450 CYP2C9 locusPharmacogenetics, 1996
- Allelic Variants of Human Cytochrome P450 2C9: Baculovirus-Mediated Expression, Purification, Structural Characterization, Substrate Stereoselectivity, and Prochiral Selectivity of the Wild-Type and I359L Mutant FormsArchives of Biochemistry and Biophysics, 1996
- The role of the CFP2C9-Leu 359 allelic variant in the tolbutamide polymorphismPharmacogenetics, 1996
- Detection of CYP2C9 polymorphism based on the polymerase chain reaction in ChinesePharmacogenetics, 1995
- Oral Anticoagulant Therapy—50 Years LaterArchives of Internal Medicine, 1993
- Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactionsChemical Research in Toxicology, 1992
- Genetic polymorphism of S-mephenytoin hydroxylationPharmacology & Therapeutics, 1989
- A comparison of the isomers of warfarinBiochemical Pharmacology, 1966